Phillip Coffin
San Francisco Department of Public Health · Director, Substance Use Division, San Francisco Department of Public Health · Substance Use Research Unit, San Francisco Department of Public Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Phillip Coffin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:52 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07464873 · Reliability, Validity, and Acceptability of a Novel Visual Scale for Estimating Daily Methamphetamine Use Among People Who Use MethamphetaminePhillip Coffin, MD, MIA · not yet recruiting · Methamphetamine Disorders · principal investigator
- Ph1NCT04614584 · Mirtazapine and Methamphetamine Drug-drug Interaction StudySan Francisco Department of Public Health · completed · Methamphetamine Use Disorder, Drug Interaction, Cardiovascular Abnormalities · principal investigator
- Ph4NCT04523519 · PrEP Intervention for People Who Inject Substances and Use MethamphetamineSan Francisco Department of Public Health · completed · HIV Infections · principal investigator
- N/ANCT02093559 · Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Naloxone RecipientsSan Francisco Department of Public Health · completed · Opioid-Related Disorders, Drug Overdose · principal investigator
- Ph2NCT01449565 · Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)San Francisco Department of Public Health · completed · Amphetamine-Related Disorders · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Behavioral Safety and Fentanyl Education: BSAFER01DA064340 · NIDA · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2025 to 2026 · $622,396 awarded in 2026Same name and institution; not confirmed by an ID
- Glutide for Ending MethamphetamineUG3DA063329 · NIDA · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2025 to 2026 · $862,498 awarded in 2026Same name and institution; not confirmed by an ID
- Midcareer K24 Award for Mentoring and Patient-Oriented ResearchK24DA042720 · NIDA · SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH · fiscal years 2016 to 2026 · $199,597 awarded in 2026Same name and institution; not confirmed by an ID
- PRIME: PrEP Intervention for people who Inject MEthamphetamineR01DA051850 · NIDA · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2020 to 2024 · $738,862 awarded in 2024Grant number is on one of their registry trials
- Leveraging Psychological Autopsies to Accelerate Research into Stimulant Overdose MortalityR01CE003364 · NCIPC · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2021 to 2023 · $362,432 awarded in 2023Same name and institution; not confirmed by an ID
- Repeated-dose behavioral intervention to reduce opioid overdose: a two-site randomized-controlled efficacy trialR01DA045690 · NIDA · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2018 to 2022 · $692,881 awarded in 2022Same name and institution; not confirmed by an ID
- Mirtazapine for methamphetamine use disorder: drug-drug interaction studyU01DA051080 · NIDA · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2020 to 2021 · $2,182,386 awarded in 2021Same name and institution; not confirmed by an ID
- Cohort Study of Opioids, Pain, and Safety in an era of Changing Policy (COPING)R01DA040189 · NIDA · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2016 to 2020 · $394,363 awarded in 2020Same name and institution; not confirmed by an ID
- SHARP: Summer HIV/AIDS Research ProgramR25DA043441 · NIDA · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2017 to 2019 · $104,519 awarded in 2019Same name and institution; not confirmed by an ID
- Hepatitis C Treatment As Prevention Pilot Study with Ledipasvir-Sofosbuvir Among People Actively Injecting Drugs (TasP-C Pilot)R34DA039333 · NIDA · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2015 to 2017 · $114,015 awarded in 2017Same name and institution; not confirmed by an ID
- Mirtazapine for the treatment of methamphetamine dependence among MSM with high-rR01DA034527 · NIDA · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2013 to 2017 · $406,960 awarded in 2017Same name and institution; not confirmed by an ID
- Substance use outcomes of opioid dose reduction and discontinuationU01CE002793 · NCIPC · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2016 to 2017 · $399,558 awarded in 2017Same name and institution; not confirmed by an ID
- Naltrexone for the treatment of Actively-Using Met-Dependent MSM with High-Risk BR01DA031678 · NIDA · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2014 to 2016 · $228,809 awarded in 2016Grant number is on one of their registry trials
- Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among NaloR34DA037194 · NIDA · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2014 to 2016 · $137,587 awarded in 2016Same name and institution; not confirmed by an ID
- An Assessment of Opioid Overdoses in San Francisco from 2010 through 2012R03DA038084 · NIDA · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2014 to 2015 · $54,076 awarded in 2015Same name and institution; not confirmed by an ID
- Naloxone prescription for Opioid Safety Evaluation (NOSE)R21DA036776 · NIDA · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2013 to 2014 · $166,421 awarded in 2014Same name and institution; not confirmed by an ID
- Aripiprazole to reduce methamphetamine use among MSM with high-risk HIV behaviorsR01DA023387 · NIDA · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2011 · $312,366 awarded in 2011Same name and institution; not confirmed by an ID
- Reducing HIV risk among episodic substance-using MSMUR6PS000684 · NCHHSTP · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2011 · $319,604 awarded in 2011Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:52 UTC. The ranking covers the 200 most relevant of 26 PubMed records, and a shared surname and initials can bring in a namesake. All 26 on PubMed
- Bupropion and Naltrexone in Methamphetamine Use Disorder.N Engl J Med · 2021212 citationsRCR 18.0
- Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial.JAMA Psychiatry · 2020112 citationsRCR 8.3
- Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial.Addiction · 201355 citationsRCR 2.3
- Substance use and drinking outcomes in Personalized Cognitive Counseling randomized trial for episodic substance-using men who have sex with men.Drug Alcohol Depend · 201435 citationsRCR 1.8
- Adapted personalized cognitive counseling for episodic substance-using men who have sex with men: a randomized controlled trial.AIDS Behav · 201433 citationsRCR 1.5
- Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial.Addiction · 201833 citationsRCR 2.2
- 33 citationsRCR 1.9
- Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for Nondependent Methamphetamine-Using and Binge-Drinking Men Who Have Sex with Men.J Acquir Immune Defic Syndr · 201628 citationsRCR 1.6
- Race/ethnicity, education, and age are associated with engagement in ecological momentary assessment text messaging among substance-using MSM in San Francisco.J Subst Abuse Treat · 201725 citationsRCR 1.6
- 20 citationsRCR 1.0